Telemedical

Telemedical Telemedical este un site care oferă informații de ultimă oră validate de profesioniști din dom

Telemedical este deschis tuturor clinicilor si cabinetelor individuale care doresc sa se afilieze sistemului nostru pentru a oferi, impreuna,servicii medicale de cea mai buna calitate.

21/02/2026
21/02/2026
21/02/2026
21/02/2026
21/02/2026
16/02/2026
16/02/2026

Japan has announced a major medical breakthrough with what is described as the first verified stem cell treatment for spinal injury to restore significant movement in a previously paralyzed patient. The development marks a hopeful step forward in regenerative medicine and neurological recovery research.

The therapy involves transplanting specialized stem cells into the damaged area of the spinal cord. These cells are designed to support nerve repair, reduce inflammation, and encourage reconnection between disrupted neural pathways. In early clinical monitoring, one patient who had lost mobility following a severe spinal injury regained the ability to stand and walk with assistance.

Spinal cord injuries are among the most challenging conditions in modern medicine because nerve tissue has limited ability to regenerate naturally. Traditional treatments focus mainly on rehabilitation and symptom management rather than repair of the damaged cord itself.

Researchers caution that while the results are promising, the treatment is still in carefully controlled clinical stages. Larger trials will be necessary to confirm safety, effectiveness, and long term outcomes across diverse patient groups.

If further validated, this approach could redefine recovery possibilities for individuals living with paralysis. The breakthrough highlights how advances in stem cell science are steadily moving from experimental theory toward practical clinical application.

16/02/2026

A hidden risk inside motherhood's miracle. A new study has raised serious concerns about how the uterus is closed after cesarean deliveries, revealing that the most commonly used method may carry hidden dangers for long-term maternal health.
Researchers found that single-layer suturing, a technique widely used to close the uterine incision, could increase the risk of uterine rupture in future pregnancies. It may also lead to complications like chronic pelvic pain, abnormal bleeding, and problems with placenta attachment. These risks often stay undetected for years, surfacing only when the next pregnancy or medical issue occurs.
The uterus, after a C-section, requires strong healing. But when closure isn’t done in a way that supports long-term tissue integrity, it can result in thinning of the uterine wall and a higher chance of rupture during labor. This not only endangers the mother but also the baby.
Double-layer closure methods, although more time-consuming, have shown better outcomes in maintaining uterine strength. Yet many hospitals still rely on the single-layer method for speed and efficiency.
This study urges a rethinking of surgical protocols in obstetrics, prioritizing future safety over immediate convenience. The researchers call for more widespread adoption of safer closure methods and informed discussions between doctors and patients.
For millions of women, C-sections are life-saving. But they shouldn’t come with long-term risks hidden beneath the surface.
This research is a call to re-evaluate routine practices and put women’s future health first because childbirth should be the beginning of life, not the quiet start of complications.

16/02/2026
16/02/2026
16/02/2026
16/02/2026

Dr. Patrick Soon-Shiong’s company ImmunityBio has developed Anktiva, an innovative IL fifteen agonist immunotherapy designed to activate natural killer cells and T cells to help the body fight cancer.

Unlike traditional chemotherapy, which directly targets rapidly dividing cells, Anktiva works by strengthening the immune system so it can recognize and attack tumor cells more effectively.

Anktiva has received approval from the U.S. Food and Drug Administration for specific types of bladder cancer. It has also been authorized in Saudi Arabia for certain bladder and lung cancers.

Clinical studies have reported encouraging results, with some patients experiencing long lasting responses that have continued for more than four years. The treatment can be given through a subcutaneous injection and is often used alongside other therapies, offering a chemotherapy free option for eligible patients.

Researchers are now studying its possible use against additional solid tumors as part of a broader strategy to improve cancer care.

Disclaimer: This content is shared for informational purposes only and is not a substitute for professional medical advice.

Address

Strada Cernauti 50
Bucharest
022185

Telephone

+40730865730

Website

Alerts

Be the first to know and let us send you an email when Telemedical posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram